Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Completed 31Unknown 13Recruiting 12Not yet recruiting 4Withdrawn 3Active not recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 351INDUSTRY 66NETWORK 8OTHER_GOV 7FED 4NIH 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Diseases, Obstructive 1Kidney Diseases 1Dementia 1

Interventions

enzalutamide 1apalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × FED × Genitourinary × Clear all
NCT06963970 2026-04-28

PATH

VA Office of Research and Development

Phase NA Not yet recruiting
480 enrolled
Genitourinary

Dementia, Kidney Diseases, Lung Diseases, Obstructive, Neoplasms

NCT06549036 2026-04-02

Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening

VA Office of Research and Development

Phase NA Not yet recruiting
228 enrolled
Genitourinary

Prostatic Neoplasms

NCT07408830 2026-02-13

VATSIT

VA Office of Research and Development

Phase NA Not yet recruiting
2,482 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡